Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.
Serum beta 2-microglobulin, serum thymidine kinase, and commonly used prognostic parameters were investigated for their prognostic value in a well-defined group of patients with multiple myeloma (n = 207). Multivariate analysis showed hemoglobin to be the parameter of strongest prognostic value. Only albumin, serum beta 2-microglobulin and serum thymidine kinase added further prognostic information. When tested for efficiency in recognizing patients with poor (average survival time < 1 year) and good (average survival time > 5 years) prognosis, serum beta 2-microglobulin was best (80%), followed by total urinary protein (78%), hemoglobin (76%), and albumin (75%).
Diem
H
H
Institut für Klinische Chemie, Klinikum Grosshadern, Ludwig-Maximilians-Universität München.
Fateh-Moghadam
A
A
Lamerz
R
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002455:Cell Division / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000201:enzymology / Q000401:mortality; D015999:Multivariate Analysis; D011379:Prognosis; D012189:Retrospective Studies; D012709:Serum Albumin / Q000032:analysis; D015996:Survival Rate; D013937:Thymidine Kinase / Q000097:blood*; D001613:beta 2-Microglobulin / Q000378:metabolism*
D012709:Serum Albumin; D001613:beta 2-Microglobulin; D013937:Thymidine Kinase